The company has acquired its new Massachusetts site from Shire plc.

Just two years after constructing a new biologics manufacturing facility at its Laupheim, Germany site that includes two 3,000-liter stainless steel bioreactors, contract development and manufacturing organization (CDMO) Rentschler Biopharma SE is expanding again –– this time in the United States.

 The company has signed an agreement to purchase Shire’s biologics manufacturing facility in Milford, MA near Boston. Shire has been looking for a buyer for the small former Baxalta site since it completed the buyout of that firm in 2016. 

The facility covers 100,000 square feet and is reported to have approximately 100 employees. While financial terms of the deal were not disclosed, Rentschler said it would continue to manufacture products for Shire following completion of the transaction.

Shire, meanwhile, is being acquired by Japanese drug manufacturer Takeda for $58 billion.